Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
Kent KanaoTakayuki TakahashiYuta UmezawaTakashi OkabeGo KanekoSuguru ShirotakeKoshiro NishimotoMasafumi OyamaPublished in: PloS one (2022)
Our results provide important evidence regarding the superiority of abiraterone over CAB therapy and ADT alone for initial treatment for men with newly diagnosed mHNPC.